© 2021 BioShin Limited. All rights reserved.

Focus. Innovation. Growth. Culture.A Differentiated Biotech

May 2021

Established in 2018 to advance treatment options for neurology and neuro-immune disorders for patients in the Asia-Pacific region

Vision: to become the leading neuroscience biotech in the region

COMMERCIAL-STAGE LEAD ASSET • DEEP PIPELINE • INTERNATIONAL MANAGEMENT AND INVESTORS

Corporate HeadquartersPudong, Shanghai

Hong Kong biotech sector booms on buoyant markets and pandemic

Telemedicine, elderly care services, and mental health were highlighted above other areas, and these segments are likely to see rapid development in the next five years.

China’s Healthcare Revolution

MAY 2021BIOSHIN INVESTOR PRESENTATION3

China Joins ICH as Full Regulatory Member, Pledges to Implement Guidelines

China has officially released its first national list of rare diseases

Many of China’s reforms aim to streamline the regulatory processes and improve access and reimbursement to encourage developers to enter China’s healthcare market.

Coming from the Chinese words “biao” (标) and “xin”(新), which form a

phrase meaning “unique” and “at the forefront”

BioShin embodies “new” and “innovative”

BioShin: A Forward-Looking Biotech

MAY 20214

FOCUS

Build a leading biotech with the singular focus on the needs of the rapidly growing healthcare industry and patients in China and Asia

INNOVATE

Become the go-to partner for US and ex-China biotechs seeking to optimize the value of their innovative assets in the greater China and Asia healthcare markets

PURPOSE

Create value for patients and society by investing in novel, differentiated medicines to address unmet need

CULTURE

Focus on bringing together exceptional talent committed to integrity and an innovative mindset

标新

BIOSHIN INVESTOR PRESENTATION

Leadership: Deep Global and China Experience

MAY 20215

Sarah Lu MD *CHIEF MEDICAL OFFICER

David ChungCHIEF STRATEGY OFFICER

Donnie McGrath, MD MPHPRESIDENT AND EXECUTIVE CHAIRMAN

Karl Lintel, MD CHIEF EXECUTIVE OFFICER

Zoey (Zhiyao) Wang, MD MPAGENERAL MANAGER

Jonny Zhang, CPA, CFA VP FINANCE

Matthew Tan, MD VP MEDICAL

Sandy LiangHEAD OF REGULATORY AFFAIRS

Elaine HawkingsHEAD OF CLINICAL OPERATIONS

Helen ZhangSR DIRECTOR CLINICAL OPERATIONS

P R I O R P R O F E S S I O N A L R O L E S

BIOSHIN INVESTOR PRESENTATION

S E L E C T D E V E L O P M E N T E X P E R I E N C E

Mary Li Ma*CHIEF COMMERCIAL OFFICER

* Starting June 1st 2021

Growth Strategy:Reaching New Horizons with Multiple Approaches

APRIL 2021DRAFT. CONFIDENTIAL.6

Through a deep clinical

pipeline, partnerships

and discovery, BioShin

will address unmet need

in Asia-Pacific and

deliver growthLAUNCHING INNOVATIVE TREATMENTS for migraine, rare diseases, neurological disorders, and CGRP-mediated diseases

PARTNERING INNOVATION - ensure the best assets to address patient needs are brought to China and Asia-Pacific region

DISCOVERY INNOVATION -developing novel assets

Leading China-based

biotech

BIOSHIN INVESTOR PRESENTATION

Migraine in China

~90 Million People with Migraine in China2

• No innovation in over 20 years• No multinational corporate

investment in innovative medication

• NMPA: “acute treatment of migraine is an unmet medical need condition”3

Migraine: Significant Unmet Need with Limited Competition

1. http://www.ihs-headache.org/binary_data/3349_ichd-3-chinese.pdf2. Yu, S., et al., The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache, 2012. 52(4): p. 582-913. NMPA rimegepant pre-IND minutes

8

• 100% of migraine patients with/without aura1 need acutetherapy

• Rimegepant will be first oral CGRP-targeting small molecule therapy for acute treatment

• Uniquely positioned – uniqueprofile with dual indication

ACUTE TREATMENT OPPORTUNITY CURRENT PRE-CGRP LANDSCAPE

BIOSHIN INVESTOR PRESENTATION MAY 2021

Nonresponders Cannot tolerate Recurrence Cardiovascular Contraindications

Medication Overuse Headache (MOH)

Up to 55% of people do not have sufficient relief with

currently available treatments1

43% experience AEs within 24 hours2

17% to 40% experience return of migraine

pain/symptoms within 24 hours3

Approximately 2.6M in the US4

Overuse of many current acute therapies can

cause MOH5

Oral CGRP-receptor Antagonists AddressDrawbacks of Current SOC Treatments*

References: 1. Lipton RB et al. Headache. 2017;57(7):1026-1040. 2. Derry CJ et al. Cochrane Database Syst Rev. 2012;2(2):CD008615. 3. Géraud G et al. Headache. 2003;43(4):376-388. 4. Buse DC et al. Headache. 2017;57(1):31-44. 5. Schwedt TJ et al. J Headache Pain. 2018;19(1):38. *Quote: NMPA

9

BioShin is positioned to select and adapt best practices from the successful initial launch to the China market

BIOSHIN INVESTOR PRESENTATION MAY 2021

At the Forefront of the Healthcare Revolution